By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% loss for those who took Wegovy. The tirzepatide group trimmed about 7 ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

While Zepbound and Wegovy can help people lose weight and improve overall health, it’s important to work with a doctor who understands these medications before taking them. “If you want to ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

After 72 weeks of treatment, people taking Zepbound lost about 50 pounds, compared with 33 pounds for those taking Wegovy. The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight ...

For Wegovy, that was either 1.7 or 2.4 milligrams. For Zepbound, it was 10 or 15 milligrams. And here’s what researchers found. For weight loss, people on Wegovy lost about 13.7% of their body ...